STOCK TITAN
  1. Home
  2. News
  3. KTTAW

Pasithea Therapeutics Corp - KTTAW STOCK NEWS

Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.

Pasithea Therapeutics Corp (KTTAW) is a clinical-stage biotechnology company pioneering treatments for central nervous system disorders and RASopathies. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.

Access verified news about the company’s pipeline progress, including its lead candidate PAS-004 (a macrocyclic MEK inhibitor), trial design updates, and collaborations. Our curated collection features press releases on:

• Clinical trial phases
• Research partnerships
• Regulatory submissions
• Scientific publications

Bookmark this page for centralized access to Pasithea’s latest advancements in neurofibromatosis, ALS, and schizophrenia research. Check regularly for objective updates on therapeutic innovations and corporate developments shaping the biotechnology landscape.

News

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Rhea-AI Summary
Pasithea Therapeutics Corp. (KTTA) announced positive preclinical results for PAS-004, a potential treatment for Central Nervous System disorders. PAS-004 demonstrated superior anti-tumor efficacy in lung and liver cancer models compared to FDA-approved MEK inhibitors. The company plans to start a Phase 1 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) adjourns its annual meeting of stockholders to December 19, 2023, to allow additional time for stockholders to vote on proposals outlined in the Proxy Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) plans to submit PAS-004 IND application in the current quarter and begin a Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF, and NF1 mutations. The FDA's positive feedback and guidance include a recommendation to begin dosing in patients who will benefit from treatment rather than in healthy volunteers. PAS-004 was granted orphan drug designation for the treatment of NF1 in November 2020. Dr. Tiago Reis Marques, CEO of Pasithea, expressed excitement to begin testing PAS-004 in a first-in-human Phase 1 dose escalation trial in early 2024 following acceptance of the IND by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the selection of a lead therapeutic candidate for its PAS-003 program, a humanized monoclonal antibody targeting α5β1 integrin, showing promise for the treatment of ALS. The antibody has been optimized for high affinity and specificity, ready for manufacturing and IND-enabling studies. Extensive preclinical studies have validated the candidate's efficacy in both sporadic and familial ALS mouse models, with potential implications for human patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Rhea-AI Summary
Pasithea Therapeutics Corp. completes tender offer, purchasing all 5,323,451 shares at $0.70 per share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a publication in the Proceedings of the National Academy of Sciences related to its PAS-003 drug discovery program targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (ALS). The study reveals increased integrin expression in ALS patient tissues, specificity of α5 integrin in ALS, and the efficacy of a monoclonal antibody against α5 integrin in improving survival and motor function in the SOD1G93A mouse model of ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Rhea-AI Summary
Pasithea Therapeutics Corp. announces a $4.0 million tender offer to repurchase up to 5.7 million shares of its common stock at $0.70 per share. The offer is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Rhea-AI Summary
Pasithea Therapeutics Corp. confirms that its Board of Directors has formed a special committee to evaluate an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The committee is actively evaluating the proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock KTTAW logo
Pasithea Therapeutics Corp

Nasdaq:KTTAW

KTTAW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

KTTAW Stock Data

1.39M
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH